Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of AR1001 in Early Alzheimer's Disease
KCT0009137Phase 3Recruiting
- Sponsor
- AriBio
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mirodenafil in Alzheimer's disease (AD), sponsored by AriBio. Started Dec 2023; status: recruiting.
02
Drugs
mirodenafil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on KCT0009137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009137.